Dr. Michael Mauro on Toxicities of TKI Usage in Patients With CML
Michael Mauro, MD, discusses the side effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Michael Mauro, MD, hematologist, leader of the Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the side effects of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML).
In trials comparing imatinib and nilotinib, researchers see many different rates of vascular occlusive events, says Mauro. He adds that ponatinib, given to patients with CML after receiving a TKI, results in a higher number of vascular occlusive events.
Mauro says that oncologist do not know the mechanism of action that causes these toxicities in TKI usage, but he says he hopes to learn more soon from ongoing and upcoming studies. He says oncologists' best method right now is to pay attention to toxicities and adjust medication accordingly.
Resistance Spurs Evaluation of Early-Phase BTK Degraders
January 10th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome resistance.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
